LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a ...

Lifeward stock is trading higher on Thursday after the company announced that its ReWalk 7 received 510(k) clearance from the ...

Last week, Lifeward said full-year revenue rose to $25.7 million from $13.9 million. It said ReWalk Personal Exoskeleton sales increased by 130% in 2024, fueled by recently established Medicare ...

ReWalk Robotics (NASDAQ:LFWD – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $13.00 price ...

FDA clearance for the newest generation of its personal exoskeleton device, the ReWalk 7. The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury ...

REWALK ROBOTICS ($LFWD) posted quarterly earnings results on Friday, March 7th. The company reported earnings of -$0.38 per share, beating estimates of -$0.52 by $0. ...

Lifeward announced today that it received FDA 510(k) clearance for its latest-generation personal exoskeleton device, ReWalk ...

Strong conclusion to 2024 with Lifeward annual revenue of $25.7 million, up 85% from 2023. ReWalk Personal Exoskeleton sales ...

CorLife, a division of Numotion, has become the exclusive distributor for Lifeward’s ReWalk Personal Exoskeleton for people with workers’ compensation claims.